Skip to main content

Table 3 Univariate analysis for PFS and OS

From: Whole body FDG PET/MR for progression free and overall survival prediction in patients with relapsed/refractory large B-cell lymphomas undergoing CAR T-cell therapy

  

Pre-therapy

 

Δ

 
  

PFS

OS

PFS

OS

 

Variable

HR (95% CI)

p-value

FDR

HR (95% CI)

p-value

FDR

HR (95% CI)

p-value

FDR

HR (95% CI)

p-value

FDR

Basic

Age

1.02 (0.95–1.11)

0.55

0.69

1.05 (0.97–1.14)

0.21

0.37

 

BMI

0.89 (0.79–1.00)

0.051

0.15

0.96 (0.88–1.04)

0.29

0.41

 

Gender

1.12 (0.37–3.34)

0.84

0.84

1.14 (0.36–3.62)

0.83

0.83

Lugano

2 groups

 

 

1.79 (0.60–5.39)

0.29

0.51

1.19 (0.37–3.76)

0.77

0.92

Tumor

Lesions

1.01 (0.97–1.05)

0.622

0.70

0.97 (0.92–1.03)

0.27

0.41

1.44 (0.66–3.16)

0.36

0.57

1.69 (0.78–3.69)

0.18

0.37

 

MTV

1.48 (1.08–2.01)

0.00079

0.012

1.27 (0.98–1.65)

0.046

0.19

1.71 (1.11–2.64)

0.0093

0.070

1.40 (0.98–2.00)

0.058

0.19

 

TLG

1.02 (1.00–1.04)

0.0054

0.023

1.03 (1.01–1.05)

0.0014

0.024

1.46 (1.03–2.05)

0.022

0.089

1.30 (0.97–1.75)

0.071

0.19

 

Vtotal

1.63 (1.14–2.34)

0.0015

0.012

1.34 (0.96–1.88)

0.075

0.19

1.95 (1.06–3.58)

0.024

0.089

1.74 (1.03–2.92)

0.031

0.19

 

SUVmean, t0

1.06 (0.94–1.18)

0.35

0.54

1.10 (0.96–1.25)

0.18

0.37

1.34 (0.45–4.02)

0.60

0.75

1.06 (0.32–3.56)

0.93

0.98

 

SUVmax, t0

1.03 (0.99–1.06)

0.15

0.32

1.04 (0.99–1.08)

0.077

0.19

1.84 (0.87–3.90)

0.10

0.23

1.05 (0.61–1.83)

0.86

0.96

 

V, t0

1.61 (1.06–2.43)

0.013

0.043

1.90 (1.14–3.19)

0.0043

0.037

1.63 (0.96–2.76)

0.062

0.20

1.45 (0.94–2.25)

0.086

0.20

 

ADCmean, t0

0.82 (0.14–4.93)

0.83

0.84

1.28 (0.29–5.69)

0.75

0.79

0.69 (0.16–3.09)

0.63

0.75

0.44 (0.096–2.03)

0.29

0.46

 

SUVmean, t1

 

2.12 (0.73–6.19)

0.17

0.31

1.91 (0.58–6.28)

0.28

0.46

 

SUVmax, t1

 

2.34 (1.17–4.71)

0.011

0.070

1.21 (0.75–1.96)

0.43

0.58

 

V, t1

 

1.07 (0.98–1.16)

0.11

0.23

1.09 (0.99–1.19)

0.038

0.19

 

ADCmean, t1

 

0.083 (0.012–0.57)

0.0091

0.070

0.099 (0.0099–0.99)

0.040

0.19

Bone marrow

SUVmean

0.24 (0.083–0.69)

0.0044

0.023

0.28 (0.094–0.83)

0.014

0.080

10.51 (0.77–143.40)

0.073

0.20

19.74 (0.77–504.00)

0.066

0.19

 

FFmean

1.01 (0.97–1.06)

0.51

0.69

1.06 (0.99–1.14)

0.066

0.79

0.053 (0–95.21)

0.44

0.60

0 (0–1.97)

0.058

0.19

 

ADCmean

3.54 (0.047–264.10)

0.57

0.69

0.44 (0.0051–37.28)

0.71

0.19

1.42 (0.070–28.76)

0.82

0.86

3.04 (0.14–65.09)

0.48

0.60

Spleen

SUVmean

0.24 (0.051–1.12)

0.066

0.16

0.65 (0.17–2.45)

0.52

0.68

1.42 (0.028–71.07)

0.86

0.86

7.32 (0.12–462.50)

0.35

0.50

 

V

0.76 (0.45–1.29)

0.31

0.52

1.11 (0.71–1.72)

0.65

0.79

0.25 (0.0083–7.49)

0.42

0.60

0.15 (0.0061–3.51)

0.23

0.44

 

ADCmean

0.27 (0.023–3.14)

0.29

0.52

0.26 (0.029–2.27)

0.22

0.37

1.76 (0.092–33.37)

0.71

0.79

0.97 (0.049–19.05)

0.98

0.98

  1. Statistically significant results are depicted in bold (p < 0.05, FDR < 0.05). For rate of change (Δ) in tumor SUVmean, SUVmax, V and ADCmean, the target lesion was selected at t0 and at t1. Hazard ratios (HRs) for volume metrics (MTV, TLG, V and Vtotal) presented in dl unit change